Evidence map›Paper›PMID 31838658›Full record

ArticleMolecular biology reports2020

Cellular binding analysis of recombinant hybrid heteropolymer of camel hepcidin and human ferritin H chain. The unexpected human H-ferritin binding to J774 murine macrophage cells.

Mohamed Boumaiza, Maura Poli, Fernando Carmona, Michela Asperti, Alessandra Gianoncelli, Michela Bertuzzi, Paolo Arosio, Mohamed Nejib Marzouki

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Mohamed BoumaizaLaboratoire d'ingénierie des protéines et des molécules bioactives, Institut Nationale des Sciences Appliquées et de Technologie (I.N.S.A.T.), BP 676, 1080, Tunis Cedex, Tunisia. m.boumaiza@yahoo.fr.ORCID http://orcid.org/0000-0001-7686-6722
Maura PoliMolecular Biology Laboratory, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia, Italy.
Fernando CarmonaMolecular Biology Laboratory, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia, Italy.
Michela AspertiMolecular Biology Laboratory, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia, Italy.
Alessandra GianoncelliProteomics Platform, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia, Italy.
Michela BertuzziProteomics Platform, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia, Italy.
Paolo ArosioProteomics Platform, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia, Italy.
Mohamed Nejib MarzoukiLaboratoire d'ingénierie des protéines et des molécules bioactives, Institut Nationale des Sciences Appliquées et de Technologie (I.N.S.A.T.), BP 676, 1080, Tunis Cedex, Tunisia.
University of Brescia · ITBioénergétique et Ingénierie des Protéines · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferritin is a molecule with enormous potentiality in biotechnology that have been already used to encapsulate molecules, as contrast in magnetic resonance imaging and to carry epitopes. We proposed to use it to carry another key protein of iron metabolism, hepcidin that is a small hormone peptide that control systemic iron homeostasis. In this work, we purified the previously produced camel hepcidin and human H-ferritin heteropolymer (HepcH-FTH) and to monitor its binding capability toward J744 cell line in presence or absence of ferric ammonium citrate. Fused camel hepcidin and human H-ferritin monomer (HepcH) as well as the assembled HepcH-FTH heteropolymer (ratio 1:5) was easily purified by a one-step purification using size exclusion chromatography. SDS-PAGE electrophoresis of HepcH, purified from soluble and insoluble fractions, showed a single band of 24 kDa with an estimated purity of at least 90%. The purification yields of HepcH from the soluble and insoluble fractions was, respectively, of about 6.80 and 2 mg/L of bacterial culture. Time curse cellular binding assays of HepcH-FTH revealed its great potential to bind the J774 cells after 15 min of incubation. Furthermore, HepcH-FTH was able to degrade ferroportin, the unique hepcidin receptor, even after 30 min of incubation with J774 cells treated with 100 µM ferric ammonium citrate. In conclusion, we proposed ferritin as a peptide carrier to promote the association of the hybrid HepcH-FTH nanoparticle with a particular type of cell for therapeutic or diagnostic.

Indexed as

Protein MultimerizationAnimalsCamelusCell LineFerritinsHepcidinsHumansMacrophagesMiceProtein BindingRecombinant ProteinsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationFerritinsHepcidinsRecombinant ProteinsCamel hepcidinFerroportinHeteropolymer, FACHuman H-ferritinJ774 cells

Identifiers

PMID31838658
OpenAlexW2996192581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.